Published in Hematology Week, June 28th, 2004
The company is targeting a resubmission with additional clinical data from ongoing studies in both relapsed/refractory and newly diagnosed patients.
Pharmion also reaffirmed its 2004 sales guidance of $51-56 million in named patient and compassionate use sales of thalidomide, provided by the company on May 3, 2004. This was updated from previous guidance of $38-43 million.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week